Sort   by:  
 Page size 
UnknownDNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity.
Not available
S-EPMC7408442 | biostudies-literature
UnknownSarcopenia during androgen-deprivation therapy for prostate cancer.
Not available
S-EPMC3434987 | biostudies-literature
UnknownRandomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
Not available
S-EPMC3970172 | biostudies-literature
UnknownCirculating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
Not available
S-EPMC5815402 | biostudies-literature
UnknownDenosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Not available
S-EPMC3795889 | biostudies-literature
UnknownPhase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.
Not available
S-EPMC4879718 | biostudies-literature
UnknownSystemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.
Not available
S-EPMC4876355 | biostudies-literature
UnknownRandomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naive, Metastatic, Castration-Resistant Prostate Cancer.
Not available
S-EPMC5791829 | biostudies-literature
UnknownConcurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Not available
S-EPMC7655504 | biostudies-literature
UnknownReal-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
Not available
S-EPMC9184267 | biostudies-literature
Sort   by:  
 Page size